No Data
Earnings Preview: MIRM to Report Financial Results Pre-market on November 12
There's No Escaping Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Muted Revenues
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Price Target Raised to $49 From $47 at Leerink
Catalyst Watch: Netflix Earnings, Lenovo Tech Event, Paris Motor Show, and Eyes on Oil
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}